Jeffrey Tom
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jeffrey Tom has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Aimin Song
Department of Peptide Therapeutics, Genentech, South San Francisco, CA, USA
1 shared publication - Andrew Chang
Affiliation DeepSeq.AI, Inc., San Francisco, California United States of America
1 shared publication - Bryce D. Delgado
Structural Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
1 shared publication - Evelyn Hernandez
Department of BioMolecular Research, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
1 shared publication - Fei Cai
Department of Biological Chemistry, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
1 shared publication - Henry R. Maun
Department of Early Discovery Biochemistry, Genentech Inc., 1 DNA Way, South San Francisco, USA
1 shared publication
Latest Publications
- Open Access
- 9 February 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (2) , 288
A Machine Learning-Enabled Venom Peptide Platform for Rapid Drug Discovery
Background/Objectives: Nature has evolved millions of venom-derived peptides with diverse biological functions, a substantial fraction of which target complex membrane proteins such as G-protein-coupled receptors and ion channels. Many of these peptides are stabilized by multiple disulfide bonds, endowing them with exceptional structural stability and favorable pharmacological properties. Methods: Leveraging this natural diversity, we developed a robust venom peptide therapeutics discovery system built on phage display technology and constructed a library using approximately 482 venom-derived scaffolds. The library design was guided by a machine learning (ML) model capable of predicting mutation-tolerant residues that preserve peptide foldability, maximizing structural integrity and sequence diversity. Results: The resulting VCX library was evaluated through screening against four diverse targets (CD47, DLL3, IL33, and P2X7R), yielding strong binders for all four, a success rate of 100%. Furthermore, by integrating high-throughput recombinant expression of thioredoxin–venom fusion proteins along with ML-assisted affinity maturation, we rapidly identified potential leads for DLL3 binders. Conclusions: This venom-based discovery platform offers significant advantages in both functionality and developability compared with conventional peptide discovery approaches. By combining natural structural diversity, ML-guided design, and recombinant expression, it enables efficient identification of “antibody-like” binders with molecular weights much smaller than those of antibodies. Consequently, it provides a powerful strategy for developing next-generation peptide therapeutics targeting challenging protein–protein interactions and complex membrane proteins.
- 9 February 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (2) , 288
Open AccessA Machine Learning-Enabled Venom Peptide Platform for Rapid Drug Discovery
Background/Objectives: Nature has evolved millions of venom-derived peptides with diverse biological functions, a substantial fraction of which target complex membrane proteins such as G-protein-coupled receptors and ion channels. Many of these peptides are stabilized by multiple disulfide bonds, endowing them with exceptional structural stability and favorable pharmacological properties. Methods: Leveraging this natural diversity, we developed a robust venom peptide therapeutics discovery system built on phage display technology and constructed a library using approximately 482 venom-derived scaffolds. The library design was guided by a machine learning (ML) model capable of predicting mutation-tolerant residues that preserve peptide foldability, maximizing structural integrity and sequence diversity. Results: The resulting VCX library was evaluated through screening against four diverse targets (CD47, DLL3, IL33, and P2X7R), yielding strong binders for all four, a success rate of 100%. Furthermore, by integrating high-throughput recombinant expression of thioredoxin–venom fusion proteins along with ML-assisted affinity maturation, we rapidly identified potential leads for DLL3 binders. Conclusions: This venom-based discovery platform offers significant advantages in both functionality and developability compared with conventional peptide discovery approaches. By combining natural structural diversity, ML-guided design, and recombinant expression, it enables efficient identification of “antibody-like” binders with molecular weights much smaller than those of antibodies. Consequently, it provides a powerful strategy for developing next-generation peptide therapeutics targeting challenging protein–protein interactions and complex membrane proteins.